Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been giving part of cocktail to my parents for years, it has kept them going. Real results in real human randomised, double-blinded, placebo-controlled phase-II trial, all parts of the cocktail you can buy on Amazon. My motto do what you can do:
https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-023-00336-2
this seems hopeful and you can buy all these supplements on Amazon:
We showed a significant decrease of AD Assessment Scale-cognitive subscale (ADAS-Cog) score on day 84 vs day 0 (P = 0.00001, 29% improvement) in the CMA group. Moreover, there was a significant decline (P = 0.0073) in ADAS-Cog scores (improvement of cognitive functions) in the CMA compared to the placebo group in patients with higher ADAS-Cog scores.
https://pubmed.ncbi.nlm.nih.gov/36703196/
Not be be pessimistic but Alkon is 80 years old now. I think that the time for another trial has passed under his leadership.
That is not how it should work agree and we probably will never know, but enrollment has likely started and completed with their most "friendly" clinic. The results show no difference between placebo and bryo, that is a simple info they could have received - folks we see all patients progressing similarly
I think there is a likely scenario this deal was done with the management team knowing the results were poor. You don't need to unblind the data to know it was not working as there was more or less no difference across the health of the patient group. A simple call through the clinics would have provided that answer.
Best of luck and well wishes all for xmas & 2023! Unfortunate outcome, still no solution for AD.
or take a skeptics view, the folks part of the placement are trying to create that perception by buying in the open market. I do agree makes no difference for the results any of these shenanigans.
frankly it leaves me a bit puzzled, Alkon may be convinced we are good but the folks around him are doubtfull. So yes you are right everyone can sell - may need to tweak my risk down a bit if we go over 10.
driving the price up is done regularly in stocks. Most will conclude something positive is going on behind the curtain, results leaked etc and dont sell. Its a 4M share dilution, in a construct that has no risk for the investors + they get a free cash in window if they can pump the price up before results. Optics are ugly for this one. You may say its the standard presentation in the TE conference, but he went there knowing the dilution was on the way. Its bad form.
I think there will now be an attempt to drive the price up as part of the "anticipation" of good results and warrants get cashed.
he was in ThinkEquity investor conference few weeks ago convincing folks to buy. You can be 100% sure this placement was agreed before that conference, I guess he forgot to mention there that they would be diluted in a few weeks later. The only reason this is not priced lower is because of the June placement as I am guessing they did not want to price it under that as those investors are likely from the same "friends" circle. To make it up they got a zero risk construct.
wow what a shameful, deceitful behavior. Some concern growing that Alkon's enthusiasm is merely for attempts to pump up the SP so warrants can be cashed.
we may see some selling pressure from F warrants above 6.90. Total diluted is 12M after the April Es expired.
listened to the call as well. Some points
- Wrt to the INDs. If I recall well they just submitted the MS one. Trials to commence in 2023.
- I sensed the folks asking questions took the SAB changes as a confidence builder.
- Alkon stating Bryo will also somewhat tackle tau and amyloid and is multimodal
- Synthetic version can be brought in relatively fast, they have 1 gram but dont need it to complete ongoing and future trials
- they were asked whether big pharmaceuticals show interest in partnering, they kicked that question down the road
- Tuchman sounded easily irritated, Alkon performance was good
- overall agree with other posters a positive call, I do think it may lead to some more cash flowing in - buying on dips
corporate update, thats interesting. Takeover or just waking from the slumber?
excellent patent!!
In aversive learning an aversion is created toward a targeted behavior by pairing it with an unpleasant stimulus, such as a painful electric shock.
However, how acetylcholine stimulates learning beyond M1Rs remains unresolved. Here, we found that acetylcholine stimulated protein kinase C (PKC) in mouse striatal/nucleus accumbens.
Phosphoproteomic of the acetylcholine pathway enables discovery of the PKC-ß-PIX-Rac1-PAK cascade as a stimulatory signal for aversive learning
https://www.nature.com/articles/s41380-022-01643-2
thats a great theory
you have to be right with that one. I think the company could provide a bit more perspective on this in a presentation or so
my "issue" with this is that Alkon talks about regrowing the wiring, obviously there is no new wiring being formed in couple hours. It needs to be an entirely different mode of operation this instant impact.
yep lets go back to 10+!! No warrant selling pressure this time!!!
In case you missed this, here the abstract: https://app.oxfordabstracts.com/events/1565/submissions/330891/question/26079/programme-builder/download
will do, thanks!
did not know that background. In my view this is excellent research, opens up a new market segment where folks at higher risk are prescribed Brystatin. I may need to get my hands on Bryostatin myself to start my own preventative cycle at some point in time. Hopefully they are going to do the oral dose testing soon.
like this one: "Through direct regulation of the Alzheimer's disease ("AD") major risk genes (called ApoE), we may be able to extend Bryostatin's therapeutic benefits to a prevention, pre-dementia strategy"
For a long time I am suspecting Alkon is experimenting on himself....maybe he is starting to see benefits
- financials in good shape, cash burn at 3.5M per Q only.
- There was a timing update for the Fragile X: The Company plans to initiate a Phase 1 clinical trial during the first half of 2022.
well that was a positive trading day. With the warrant expiry overhang removed the thing could run....Should we get the Q report Monday?
got it
Looks its not yet granted? Ofcourse this may attract parties interested in working with SNPX just in case it gets granted
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=%2217%2F138,214%22&OS=%2217/138,214%22&RS=%2217/138,214%22
I wish it was!!! I am afraid its not, check the XBI for example
E warrants should expire today.
there is no point to do a PR now, the April warrants will expire worthless. That means they are missing some 8M USD and I would expect they will make up for that with a new share emission. Overall the company management of shareholder interests is disappointing. They need to get the stockprice up to reduce dilution.
Some tiny insider action. Looks like a vesting scheme?
learned something that they test it in skin. It could have a body wide health improving impact perhaps, that is a nice off target side effect to have!
the PR is great, improvement in vascular micro-vessels is easy to understand. Would be interesting btw if that is also triggered in the rest of the body e.g. heart
thats for sure, the stockprice indicates skepticism and indifference. My perception is that Bryostatin is "old news" for the investment community.
28 days left for the warrants and we are at 7.41. The only spike causing PR I can see is enrollment completion.